223 related articles for article (PubMed ID: 29175457)
21. Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple-negative breast cancer using radiolabeled anti-programmed death-ligand 1 monoclonal antibody.
Pang X; Liu M; Wang R; Liao X; Yan P; Zhang C
J Labelled Comp Radiopharm; 2018 Sep; 61(11):826-836. PubMed ID: 29923634
[TBL] [Abstract][Full Text] [Related]
22. A Dual-Mode Imaging Nanoparticle Probe Targeting PD-L1 for Triple-Negative Breast Cancer.
Li X; Ji Y; Chen M; Zhang S; Wang Z; Su D; Luo N
Contrast Media Mol Imaging; 2022; 2022():2431026. PubMed ID: 35694705
[TBL] [Abstract][Full Text] [Related]
23. Real-time near-infrared bioimaging of a receptor-targeted cytotoxic dendritic theranostic agent.
Wu J; Zhou Y; Li S; Qu D; Zhu WH; Tian H
Biomaterials; 2017 Mar; 120():1-10. PubMed ID: 28011190
[TBL] [Abstract][Full Text] [Related]
24. Development of redox-responsive theranostic nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of tumor.
Yang X; Shi X; Ji J; Zhai G
Drug Deliv; 2018 Nov; 25(1):780-796. PubMed ID: 29542333
[TBL] [Abstract][Full Text] [Related]
25. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
Nedrow JR; Josefsson A; Park S; Ranka S; Roy S; Sgouros G
J Nucl Med; 2017 Oct; 58(10):1560-1566. PubMed ID: 28522738
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
Tang X; Rao J; Yin S; Wei J; Xia C; Li M; Mei L; Zhang Z; He Q
Eur J Pharm Sci; 2019 Jan; 127():161-174. PubMed ID: 30366077
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of lipidic organoalkoxysilanes for the self-assembly of liposomal nanohybrid cerasomes with controlled drug release properties.
Liang X; Li X; Jing L; Xue P; Jiang L; Ren Q; Dai Z
Chemistry; 2013 Nov; 19(47):16113-21. PubMed ID: 24123292
[TBL] [Abstract][Full Text] [Related]
28. Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based "combo" nanoagent together with PD-L1 blockade in reversing multidrug resistance.
Jiang W; Su L; Ao M; Guo X; Cheng C; Luo Y; Xie Z; Wang X; Wang J; Liu S; Cao Y; Li P; Wang Z; Ran H; Zhou Z; Ren J
J Nanobiotechnology; 2021 Jul; 19(1):200. PubMed ID: 34225744
[TBL] [Abstract][Full Text] [Related]
29. Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer.
Kong S; Liu Q; Chen Y; Liang B; Zhou Y; Lin J; Xie M; Qiu L
Mol Pharm; 2024 Jan; 21(1):255-266. PubMed ID: 38093483
[TBL] [Abstract][Full Text] [Related]
30. PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer.
Sun Z; Zhang Y; Cao D; Wang X; Yan X; Li H; Huang L; Qu X; Kong C; Qin H; Wang M; Xu W; Liang L
Drug Deliv; 2018 Nov; 25(1):1746-1755. PubMed ID: 30394118
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles.
Pham LM; Poudel K; Ou W; Phung CD; Nguyen HT; Nguyen BL; Karmacharya P; Pandit M; Chang JH; Jeong JH; Ku SK; Yong CS; Choi HG; Kim JO
Int J Pharm; 2021 Aug; 605():120816. PubMed ID: 34161810
[TBL] [Abstract][Full Text] [Related]
32. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
Lu Q; Qi S; Li P; Yang L; Yang S; Wang Y; Cheng Y; Song Y; Wang S; Tan F; Li N
J Mater Chem B; 2019 Apr; 7(15):2499-2511. PubMed ID: 32255127
[TBL] [Abstract][Full Text] [Related]
33. Multifunctional theranostic contrast agent for photoacoustics- and ultrasound-based tumor diagnosis and ultrasound-stimulated local tumor therapy.
Moon H; Kang J; Sim C; Kim J; Lee H; Chang JH; Kim H
J Control Release; 2015 Nov; 218():63-71. PubMed ID: 26432554
[TBL] [Abstract][Full Text] [Related]
34. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Loo K; Daud AI
Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy.
Li Y; Liu G; Ma J; Lin J; Lin H; Su G; Chen D; Ye S; Chen X; Zhu X; Hou Z
J Control Release; 2017 Jul; 258():95-107. PubMed ID: 28501673
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.
Heskamp S; Wierstra PJ; Molkenboer-Kuenen JDM; Sandker GW; Thordardottir S; Cany J; Olive D; Bussink J; Boerman OC; Dolstra H; Aarntzen EHJG; Hobo WA
Cancer Immunol Res; 2019 Jan; 7(1):150-161. PubMed ID: 30459153
[TBL] [Abstract][Full Text] [Related]
39. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
40. Redox-responsive dextran based theranostic nanoparticles for near-infrared/magnetic resonance imaging and magnetically targeted photodynamic therapy.
Ding Z; Liu P; Hu D; Sheng Z; Yi H; Gao G; Wu Y; Zhang P; Ling S; Cai L
Biomater Sci; 2017 Mar; 5(4):762-771. PubMed ID: 28256661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
